ICD-10-PCS code to provide accurate documentation of sepsis diagnosis for medical claims using SeptiCyte® RAPID

ICD-10-PCS代码使用SeptiCyte®RAPID为医疗索赔提供准确的脓毒症诊断文件

SEATTLE and BRISBANE, Australia, Sept. 6, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostics company focused on improving outcomes for suspected sepsis patients, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted an International Classification of diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) code for Immunexpress' host response molecular test for sepsis, SeptiCyte® RAPID.

西雅图和布里斯班，澳大利亚，2023年9月6日/PRNewswire/-Immunexpress，Pty Ltd.，一家专注于改善疑似败血症患者预后的分子诊断公司，今天宣布美国医疗保险和医疗补助服务中心（CMS）已授予国际疾病分类，第十修订版，程序编码系统（ICD-10-PCS）用于Immunexpress的脓毒症宿主反应分子测试代码，SeptiCyte®RAPID。

The diagnosis code is designated as XXE5X38..

诊断代码指定为XXE5X38。。

ICD-10 is a system designed by the World Health Organization that is utilized worldwide by providers and payers to classify and code diagnoses and procedures for claims processing and reimbursement, and to track patient treatments and outcomes. In the United States, CMS has adopted this system to support the country's healthcare infrastructure.

ICD-10是由世界卫生组织设计的系统，供应商和付款人在全球范围内利用该系统对索赔处理和报销的诊断和程序进行分类和编码，并跟踪患者的治疗和结果。在美国，CMS采用该系统来支持该国的医疗保健基础设施。

ICD-10-PCS codes are procedure code sets applicable to all healthcare settings. .

ICD-10-PCS代码是适用于所有医疗保健设置的程序代码集。 .

'Assigning this ICD-10-PCS code signifies another milestone in the expanding adoption of SeptiCyte RAPID in U.S. healthcare systems as it provides coders with a classification for billing and claims reimbursement for sepsis,' commented Rollie Carlson, Ph.D., Chief Executive Officer of Immunexpress. 'Sepsis is an under-diagnosed and under-reported condition in hospitals, and this ICD-10-PCS code will help to ensure that use of our sepsis-detecting technology is more accurately documented in medical claims.'.

“分配这个ICD-10-PCS代码意味着在美国医疗保健系统中扩大采用SeptiCyte RAPID的另一个里程碑，因为它为编码人员提供了脓毒症计费和索赔报销的分类，”Immunexpress首席执行官Rollie Carlson博士评论说脓毒症在医院中是一种诊断不足和报告不足的疾病，该ICD-10-PCS代码将有助于确保在医疗索赔中更准确地记录我们脓毒症检测技术的使用。

About SeptiCyte® RAPID

关于SeptiCyte®RAPID

SeptiCyte® RAPID is a sample-to-answer, cartridge-based, host response molecular test for sepsis using reverse transcription polymerase chain reaction (RT-PCR) to quantify the relative expression levels of host response genes isolated from whole blood. SeptiCyte® RAPID is used in conjunction with clinical assessments, vital signs and laboratory findings as an aid to differentiate infection-positive (sepsis) from infection-negative systemic inflammation response syndromes in patients with escalating signs and symptoms of critical illness.

SeptiCyte®RAPID是使用逆转录聚合酶链反应（RT-PCR）定量从全血中分离的宿主反应基因的相对表达水平的脓毒症样本回答，基于盒的宿主反应分子检测。SeptiCyte®RAPID与临床评估，生命体征和实验室检查结果结合使用，有助于区分感染阳性（败血症）和感染阴性全身炎症反应综合征，以及危重疾病体征和症状升级的患者。

SeptiCyte® RAPID generates a score (SeptiScore®) that falls within four discrete interpretation bands based on the increasing likelihood of sepsis. SeptiCyte® RAPID is intended for in-vitro diagnostic use and runs on the Biocartis Idylla™ Platform, and Immunexpress has a commercialization partnership with Biocartis in Europe..

SeptiCyte®RAPID根据脓毒症可能性的增加产生一个分数（SeptiScore®），该分数属于四个离散的解释范围。SeptiCyte®RAPID适用于体外诊断用途，可在Biocartis Idylla上运行™ 平台，Immunexpress与欧洲的Biocartis建立了商业合作伙伴关系。。

SeptiCyte® RAPID is CE Marked as a near-patient sample-to-answer test in European Union (EU) member countries and those harmonized with the EU IVD Directive (98/79/EC). As of November 2021, SeptiCyte® RAPID has been FDA cleared for use in hospitalized patients suspected of sepsis.

SeptiCyte®RAPID在欧盟（EU）成员国和符合欧盟IVD指令（98/79/EC）的成员国被CE标记为接近患者的样本回答测试。截至2021年11月，SeptiCyte®RAPID已被FDA批准用于疑似败血症的住院患者。

About Immunexpress

关于Immunexpress

Immunexpress is a molecular diagnostic company, based in Brisbane and Seattle, committed to improving outcomes for patients suspected of sepsis. Immunexpress' SeptiCyte® technology can assess a patient's dysregulated immune response by quantifying and analyzing gene expression from whole blood, providing actionable results in about an hour from sepsis suspicion, to guide the physician in optimizing patient management decisions.

Immunexpress是一家位于布里斯班和西雅图的分子诊断公司，致力于改善疑似败血症患者的预后。Immunexpress的SeptiCyte®技术可以通过量化和分析全血中的基因表达来评估患者失调的免疫反应，在脓毒症怀疑的大约一小时内提供可行的结果，以指导医生优化患者管理决策。

SeptiCyte® RAPID is a lab test for sepsis that combines SeptiCyte® technology with the ease-of-use of the revolutionary Biocartis' Idylla™ Platform; it supports differentiating infection (bacterial, viral, fungal) positive sepsis that could lead to organ dysfunction and death from patients with less serious infection negative systemic inflammation.

SeptiCyte®RAPID是一种脓毒症的实验室测试，结合了SeptiCyte®技术和革命性的生物技术Idylla的易用性™ 平台；它支持区分感染（细菌，病毒，真菌）阳性败血症，这可能导致器官功能障碍和感染阴性全身炎症较轻的患者死亡。

This powerful test enhances early sepsis detection and can strongly support its diagnosis in the crucial first hour(s) that determines clinical outcome. SeptiCyte® RAPID also has a high potential to reduce sepsis associated healthcare costs. .

这个强大的测试增强了早期脓毒症的检测，并可以在决定临床结果的关键的第一个小时内强烈支持其诊断。SeptiCyte®RAPID也具有降低败血症相关医疗成本的巨大潜力。 .

For more information, visit http://www.septicyte.com and  http://www.immunexpress.com/. Follow Immunexpress on Twitter and LinkedIn.

For more information, visit http://www.septicyte.com and  http://www.immunexpress.com/. Follow Immunexpress on Twitter and LinkedIn.

Media Contacts:

媒体联系人：

Scott StachowiakRusso Partners, LLC[email protected]

Scott StachowiakRusso Partners，LLC[电子邮件保护]

Maddie StabinskiRusso Partners, LLC [email protected]

Maddie StabinsiRusso Partners，LLC[电子邮件保护]

SOURCE Immunexpress, Inc.

SOURCE Immunexpress，Inc。